New genetic risk factors for depression identified across global populations

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity.

Low-molecular weight human interleukin-1β antagonist discovered

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

September 11, 2023

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme – Psychedelic Alpha

Speaking at TD Cowen’s September 26th panel, Advancement in Psychedelic Therapies for Neuropsychiatry, execs from atai Life Sciences, Cybin, and GH Research fielded questions on Lykos’ new drug application (NDA), psychedelic trial design, and

October 11, 2024

Are Deadly Strep Infections on the Rise? Here’s What to Know

Japan has been experiencing a dramatic rise in cases of streptococcal toxic shock syndrome (STSS), according to the country’s National Institute of Infectious Diseases (NIID)

March 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.